Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
including murine and rat mechanistic breast cancer models driven by MMTV–Wnt1 and a human head and neck squamouscell carcinoma model (HN30)
20-6-4-15)21-7-5-16/h2-3
is a small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity
NR2E1) modulator (EC50=1μM
Paliperidone - CAS# 144598-75-4 Catalog No.:M11180-2 including murine and rat mechanisticPaliperidone is a dopamine antagonist and 5 HT2A antagonist of the atypical antipsychotic class of medications. It is developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once daily dosing. Paliperidone has antagonist effect at 1 and 2 adrenergic receptors and at H1 histamine receptors. It does not bind to muscarinic acetylcholine receptors. In addition,
US$ 196.00
US$ 40.00
US$ 169.50
US$ 313.50